Hosted on MSN12mon
Teva’s Ajovy yields positive data in post-hoc migraine analysisThe Phase III trial evaluated the safety and efficacy of monthly and quarterly subcutaneous injections of Ajovy compared to placebo in subjects with chronic migraine or episodic migraine.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback